Participants
bipolar I depression
Study participants were 347 children and adolescents with bipolar I depression enrolled in a previously published randomized placebo-controlled trial of flexibly-dosed lurasidone 20-80 mg/d followed by a two-year, open-label extension study in which participants were either continued on lurasidone or switched from placebo to lurasidone 20-80 mg/d, flexibly dosed (Clinicaltrials.gov identifier: NCT02046369, NCT01914393) [